Condition
Multiple System Atrophy (MSA) With Orthostatic Hypotension
Total Trials
4
Recruiting
2
Active
2
Completed
2
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 37/100
Termination Rate
0.0%
0 terminated out of 4 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
50%
1 of 2 completed with results
Key Signals
1 with results100% success
Data Visualizations
Phase Distribution
3Total
Not Applicable (1)
Early P 1 (1)
P 2 (1)
Trial Status
Recruiting2
Completed2
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (4)
Showing 4 of 4 trials
NCT06647641Recruiting
The CurePSP Genetics Program
NCT06920134Not ApplicableRecruiting
Epidural Electrical Stimulation to Support Hemodynamic Management in Individuals With Parkinson's Disease
NCT02705755Phase 2Completed
TD-9855 Phase 2 in Neurogenic Orthostatic Hypotension (nOH)
NCT04616456Early Phase 1Completed
Effect of Verdiperstat on Microglial Activation in Well-characterized MSA Patients
Showing all 4 trials